Strategic question
Is real-world evidence in China a defensible thesis, and which ventures are emerging as category leaders?
How Galen Growth helped
From market signal to decision-ready evidence
Using HealthTech Alpha, we mapped RWE-enabled ventures in China, assessed data provenance, clinical partnerships and commercial traction, and benchmarked the category against global comparables.
Outcomes
Sharpened the investor’s RWE thesis with a traceable view of category depth, differentiation and white space in China.
Decision enabled: Enabled the investor to move from thesis hypothesis to targeted diligence on a short list of category leaders.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Macro and micro-environment analysis in RWD & RWE
The Corporate Venture Capital (CVC) arm of a global pharmaceutical company wanted to analyse a specific key APAC market to assess both the macro and micro-environment for Real World Data and Real Word Evidence to inform corporate strategy and prioritise key ventures for further engagement. By utilising Galen Growth's proven PlayBook methodology, we enabled our client to fully understand the RWD and RWE innovation environment and readiness to enable the identification and prioritisation of Digital Health ventures with the right capabilities and achievements. Further prioritisation driven by Deep Dive analysis of select ventures, to map their operating model, leading to direct engagement with their leadership team. The examination covered 1 key therapeutic area in 1 key APAC country. We screened 15 ventures and, in collaboration with our client, shortlisted 7.
Competitive analysis in genomics for a reinsurance company
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target.
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?